IMV Inc. (IMVIF)

OTCMKTS · Delayed Price · Currency is USD
0.0195
+0.0195 (1,949,900.00%)
At close: Sep 30, 2025
1,949,900%
Market Cap286.88K
Revenue (ttm)n/a
Net Income (ttm)-37.99M
Shares Out14.71M
EPS (ttm)-4.55
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume60,327
Average Volume6,883
Open0.0195
Previous Close0.0000
Day's Range0.0100 - 0.0195
52-Week Range0.0000 - 0.0195
Beta3,679.50
RSI96.55
Earnings Daten/a

About IMV Inc.

IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX, an immune-educating technology platform for treatment of solid and hematological cancers. The company’s lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and MSI-H solid tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 63
Stock Exchange OTCMKTS
Ticker Symbol IMVIF
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.